Phenotypes Associated with This Genotype

Genotype
MGI:3587412

• Allelic Composition: Cd36^tm1Mfe/Cd36^tm1Mfe
• Genetic Background: involves: 129S1/Sv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:123605 )

N • glycogen synthesis is normal

abnormal response to cardiac infarction ( J:83611 , J:112746 )

• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)

• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)

• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)

abnormal homeostasis ( J:123605 )

decreased cardiac muscle glycogen level ( J:83611 )

• decrease in glycogen levels in the heart

decreased fasting circulating glucose level ( J:56081 )

• lower fasting glucose levels

abnormal hormone level ( J:126461 )

increased circulating leptin level ( J:126461 )

• plasma levels are 2 fold higher than for controls, even when fasted

• increased leptin mRNA in adipocytes

• leptin response to intragastric glucose administration is strongly enhanced and persists at least 4 hours

decreased circulating adiponectin level ( J:126461 )

• blood levels are decreased

abnormal lipid homeostasis ( J:56081 )

• the uptake of oleate, a long chain fatty acid, by adipoctyes is reduced at low fatty acid:BSA ratios, indicating the absence of high affinity uptake in these cells

• adipocytes exhibit an increased incorporation of palmitate into diacylglycerol

• elicited peritoneal macrophages exhibit a 40-47% decrease in binding of oxidized LDL at saturation and a 63% decrease in cell association

abnormal intestinal lipid absorption ( J:123605 )

• 50% reduction in oleic acid uptake in the first third of the small intestine

• also reduced uptake in the middle third but not in the distal third

• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine

• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine

decreased intestinal cholesterol absorption ( J:123605 )

• more cholesterol retained in the intestinal lumen

• 50% reduction in cholesterol output to lymph

• cholesterol uptake in the first third of the small intestine is reduced more than 60%

• no defect in cholesterol uptake in the distal two-thirds of the small intestine

increased circulating ketone body level ( J:126461 )

• plasma beta hydroxybutyrate levels are increased

abnormal cholesterol homeostasis ( J:56081 )

• high density lipoprotein (HDL) particles are larger and contain increased phospholipid

increased circulating cholesterol level ( J:56081 )

• higher fasting and nonfasting levels of cholesterol

increased circulating HDL cholesterol level ( J:56081 )

• increase in cholesterol level is mainly due to an increase in the HDL fraction

increased fatty acids level ( J:56081 )

• higher fasting levels of nonesterified free fatty acids

abnormal triglyceride level ( J:123605 )

• reduced incorporation of glucose into triglycerides

decreased cardiac muscle triglyceride level ( J:83611 )

• decrease in triglyceride levels in the heart

increased circulating triglyceride level ( J:56081 )

• higher fasting levels of triacylglycerol, mainly within the very low density lipoprotein fraction

increased circulating VLDL triglyceride level ( J:56081 )

abnormal basal metabolism ( J:126461 )

• unadjusted metabolic rate is reduced by 15%

• rate adjusted to body weight is normal

cardiovascular system

decreased cardiac muscle glycogen level ( J:83611 )

• decrease in glycogen levels in the heart

decreased cardiac muscle triglyceride level ( J:83611 )

• decrease in triglyceride levels in the heart

cardiac hypertrophy ( J:83611 )

• increase in the heart/body weight ratio, although exhibit no significant differences in body and heart weights

abnormal cardiovascular system physiology ( J:83611 , J:112746 )

• heart exhibits a significant decrease in palmitate oxidation and ATP levels, however cardiac output and end-diastolic pressure is normal under nonischemic conditions (J:83611)

• lower palmitate oxidation rates relative to controls offset by increased glucose oxidation levels with normal ATP production in another study (J:112746)

• cardiac work in non-ischemic hearts elevated relative to controls in another study (J:112746)

increased cardiac muscle cell glucose uptake ( J:83611 )

• increase in glucose uptake in the heart

abnormal response to cardiac infarction ( J:83611 , J:112746 )

• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)

• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)

• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)

muscle

decreased cardiac muscle glycogen level ( J:83611 )

• decrease in glycogen levels in the heart

decreased cardiac muscle triglyceride level ( J:83611 )

• decrease in triglyceride levels in the heart

increased cardiac muscle cell glucose uptake ( J:83611 )

• increase in glucose uptake in the heart

growth/size/body

cardiac hypertrophy ( J:83611 )

• increase in the heart/body weight ratio, although exhibit no significant differences in body and heart weights

decreased body size ( J:123605 , J:126461 )

• body size smaller than in controls (J:123605)

• weight difference from controls significant after 12 weeks of age (J:126461)

slow postnatal weight gain ( J:126461 )

• gain less weight than controls

• weight difference from controls significant after 12 weeks of age

digestive/alimentary system

abnormal small intestine morphology ( J:123605 )

• small intestine is longer than in controls

abnormal intestinal absorption ( J:123605 )

increased intestinal glucose absorption ( J:123605 )

• increased glucose uptake rate in the first third of the small intestine

abnormal intestinal lipid absorption ( J:123605 )

• 50% reduction in oleic acid uptake in the first third of the small intestine

• also reduced uptake in the middle third but not in the distal third

• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine

• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine

decreased intestinal cholesterol absorption ( J:123605 )

• more cholesterol retained in the intestinal lumen

• 50% reduction in cholesterol output to lymph

• cholesterol uptake in the first third of the small intestine is reduced more than 60%

• no defect in cholesterol uptake in the distal two-thirds of the small intestine

adipose tissue

abnormal fat pad morphology ( J:126461 )

• epididymal fat pads weigh less than in controls

decreased percent body fat/body weight ( J:126461 )

• total body fat about 38% lower than in controls

• lean mass normal

skeleton

decreased bone mass ( J:126461 )

• significantly reduced bone mass

behavior/neurological

abnormal food intake ( J:126461 )

• food intake reduced 20%

cellular

increased cardiac muscle cell glucose uptake ( J:83611 )

• increase in glucose uptake in the heart

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
platelet-type bleeding disorder 10		DOID:0111046	OMIM:608404	J:56081